Deutsch English Français

Contact

EP2313111

European procedure

Quick help

Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...

News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...

Extract from the Register of European Patents

EP About this file: EP2313111

EP2313111 - TOLL-LIKE RECEPTOR AGONIST FORMULATIONS AND THEIR USE [Right-click to bookmark this link]
Status	No opposition filed within time limit Status updated on 11.07.2014 Database last updated on 25.09.2024
Most recent event Tooltip	22.06.2018	Lapse of the patent in a contracting state New state(s): MK	published on 25.07.2018 [2018/30]
Applicant(s)	For all designated states VentiRx Pharmaceuticals, Inc. 1191 Second Avenue, Suite 1105 Seattle, WA 98101 / US
	[2014/01]
Former [2011/17]	For all designated states Ventirx Pharmaceuticals, Inc. 12651 High Bluff Drive Suite 200 San Diego, CA 92130 / US
Inventor(s)	01 / HOWBERT, J., Jeffry 6106 232nd Avenue NE Redmond, WA 98053 / US
	02 / DUVVURI, Muralikrishna 104 Bristol Drive Chapel Hill, NC 27516 / US
	03 / HERSHBERG, Rob 900 Lenora Street, 1103 Seattle, WA 98121 / US
	04 / DIETSCH, Greg 17732 105th Avenue SE Snohomish, WA 98296 / US
	[2011/30]
Former [2011/21]	01 / HOWBERT, J., Jeffry 6106 232nd Avenue NE Redmond, WA 98053 / US
	02 / DUVVURI, Muralikrishna 5544 Sunlight Drive, 288 Durham, NC 27707 / US
	03 / HERSHBERG, Rob 900 Lenora Street, 1103 Seattle, WA 98121 / US
	04 / DIETSCH, Greg 17732 105th Avenue SE Snohomish, WA 98296 / US
Former [2011/19]	01 / HOWBERT, J., Jeffry 6106 232nd Avenue NE Redmond, WA 98053 / US
	02 / DUVVURI, Muralikrishna 5544 Sunlight Drive, 208 Durham, NC 27707 / US
	03 / HERSHBERG, Rob 910 Lenora Street, S905 Seattle, WA 98121 / US
	04 / DIETSCH, Greg 17732 105th Avenue SE Snohomish, WA 98296 / US
Former [2011/17]	01 / HOWBERT, J., Jeffry 6106 232nd Avenue NE Redmond Washington 98053 / US
	02 / DUVVURI, Muralikrishna 5544 Sunlight Drive 208 Durham NC 27707 / US
	03 / HERSHBERG, Rob 910 Lenora Street S905 Seattle WA 98121 / US
	04 / DIETSCH, Greg 17732 105th Avenue SE Snohomish WA 98296 / US
Representative(s)	Mintz Levin Cohn Ferris Glovsky and Popeo LLP Alder Castle 10 Noble Street London EC2V 7JX / GB
	[2013/15]
Former [2011/17]	Crump, Julian Richard John, et al Mintz Levin Cohn Ferris Glovsky & Popeo Intellectual Property LLP Alder Castle 10 Noble Street London EC2V 7JX / GB
Application number, filing date	09803657.7	31.07.2009
	[2011/17]
	WO2009US52422
Priority number, date	US20080137694P	01.08.2008 Original published format: US 137694 P
	[2011/17]
Filing language	EN
Procedural language	EN
Publication	Type:	A1 Application with search report
	No.:	WO2010014913
	Date:	04.02.2010
	Language:	EN
	[2010/05]
	Type:	A1 Application with search report
	No.:	EP2313111
	Date:	27.04.2011
	Language:	EN
	The application published by WIPO in one of the EPO official languages on 04.02.2010 takes the place of the publication of the European patent application.
	[2011/17]
	Type:	B1 Patent specification
	No.:	EP2313111
	Date:	04.09.2013
	Language:	EN
	[2013/36]
Search report(s)	International search report - published on:	US	04.02.2010
	(Supplementary) European search report - dispatched on:	EP	26.07.2011
Classification	IPC:	A61K9/08, A61K31/724, A61K47/00, A61K9/00, A61K9/19, // A61K31/395, A61K47/48, A61P35/00, A61P31/12	[2013/12]
	CPC:	A61K31/55 (EP,US); A61K31/724 (EP,US); A61K47/40 (US); A61K47/6951 (EP,US); A61K9/0019 (EP,US); A61K9/08 (EP,US); (+) A61K9/19 (EP,US); A61P17/00 (EP); A61P31/00 (EP); A61P31/12 (EP); A61P35/00 (EP); A61P37/08 (EP); B82Y5/00 (EP,US); C07D223/16 (EP,US); C08B37/0012 (EP,US); Y02A50/30 (EP,US) (-)
	Former IPC [2011/17]	A61K39/395
Designated contracting states	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, SM, TR [2011/17]
Title	German:	TOLL-REZEPTORAGONISTEN-FORMULIERUNGEN UND IHRE VERWENDUNG	[2011/17]
	English:	TOLL-LIKE RECEPTOR AGONIST FORMULATIONS AND THEIR USE	[2011/17]
	French:	FORMULATIONS D'AGONISTE DES RÉCEPTEURS DE TYPE TOLL ET LEUR UTILISATION	[2011/17]
Entry into regional phase	31.01.2011	National basic fee paid
	31.01.2011	Search fee paid
	31.01.2011	Designation fee(s) paid
	31.01.2011	Examination fee paid
Examination procedure	31.01.2011	Examination requested [2011/17]
	13.02.2012	Amendment by applicant (claims and/or description)
	09.03.2012	Despatch of a communication from the examining division (Time limit: M04)
	13.07.2012	Reply to a communication from the examining division
	27.03.2013	Communication of intention to grant the patent
	16.07.2013	Fee for grant paid
	16.07.2013	Fee for publishing/printing paid
Divisional application(s)	The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is 09.03.2012
Opposition(s)	05.06.2014	No opposition filed within time limit [2014/33]
Fees paid	Renewal fee
	25.07.2011	Renewal fee patent year 03
	25.07.2012	Renewal fee patent year 04
	29.07.2013	Renewal fee patent year 05
Opt-out from the exclusive Tooltip competence of the Unified Patent Court	See the Register of the Unified Patent Court for opt-out data
	Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition Tooltip	BG	04.09.2013
	CY	04.09.2013
	EE	04.09.2013
	HR	04.09.2013
	LT	04.09.2013
	LV	04.09.2013
	MK	04.09.2013
	MT	04.09.2013
	RO	04.09.2013
	SI	04.09.2013
	SK	04.09.2013
	SM	04.09.2013
	GR	05.12.2013
	IS	04.01.2014
	[2018/30]
Former [2016/28]	BG	04.09.2013
	CY	04.09.2013
	EE	04.09.2013
	HR	04.09.2013
	LT	04.09.2013
	LV	04.09.2013
	MT	04.09.2013
	RO	04.09.2013
	SI	04.09.2013
	SK	04.09.2013
	SM	04.09.2013
	GR	05.12.2013
	IS	04.01.2014
Former [2016/22]	CY	04.09.2013
	EE	04.09.2013
	HR	04.09.2013
	LT	04.09.2013
	LV	04.09.2013
	RO	04.09.2013
	SI	04.09.2013
	SK	04.09.2013
	SM	04.09.2013
	GR	05.12.2013
	IS	04.01.2014
Former [2014/23]	CY	04.09.2013
	EE	04.09.2013
	HR	04.09.2013
	LT	04.09.2013
	LV	04.09.2013
	RO	04.09.2013
	SI	04.09.2013
	SK	04.09.2013
	GR	05.12.2013
	IS	04.01.2014
Former [2014/22]	CY	04.09.2013
	HR	04.09.2013
	LT	04.09.2013
	LV	04.09.2013
	RO	04.09.2013
	SI	04.09.2013
	GR	05.12.2013
Former [2014/18]	CY	04.09.2013
	HR	04.09.2013
	LT	04.09.2013
	LV	04.09.2013
	SI	04.09.2013
	GR	05.12.2013
Former [2014/12]	CY	17.07.2013
	HR	04.09.2013
	LT	04.09.2013
	LV	04.09.2013
	SI	04.09.2013
	GR	05.12.2013
Former [2014/10]	CY	17.07.2013
	HR	04.09.2013
	LT	04.09.2013
Former [2014/09]	HR	04.09.2013
	LT	04.09.2013
Former [2014/08]	LT	04.09.2013
Documents cited:	Search	[XY]WO9612493 (MERCK & CO INC [US], et al) [X] 1,7,8,10,11 * See page 2, second paragraph: beta cyclodextrin compositions for increasing bioavailability and absorption of pharmaceutically active compounds. See examples 1-7: compositions comprising beta cyclodextrin and a benzoazepine compound. See claim 2: use to treat HIV * [Y] 1-15;
		[XY]WO9855148 (JANSSEN PHARMACEUTICA NV [BE], et al) [X] 1,7,8,10 * See page 2, lines 4-20; page 5, lines 30-35; examples 2, 8: pharmaceutical compositions comprising a b-benzoazepine and a cyclodextrin as solubility enhancer * [Y] 1-15;
		[Y] - RAJEWSKI R A ET AL, "PHARMACEUTICAL APPLICATIONS OF CYCLODEXTRINS. 2. IN VIVO DRUG DELIVERY", JOURNAL OF PHARMACEUTICAL SCIENCES, AMERICAN PHARMACEUTICAL ASSOCIATION, WASHINGTON, US, (19961101), vol. 85, no. 11, doi:10.1021/JS960075U, ISSN 0022-3549, pages 1142 - 1169, XP000629515 [Y] 1-15 * See abstract and table 1: beta cyclodextrin and sulfobutylether of cyclodextrin for use in drug delivery for parenteral and other delivery routes * DOI: http://dx.doi.org/10.1021/js960075u
		[Y] - CHALLA R ET AL, "Cyclodextrins in drug delivery: an updated review", AAPS PHARMSCITECH, SPRINGER NEW YORK LLC, US, (20051014), vol. 6, no. 2, doi:10.1208/PT060243, ISSN 1530-9932, pages E329 - E357, XP008136705 [Y] 1-15 * See abstract and table 1: beta cyclodextrin and sulfobutylether of cyclodextrin for use in drug delivery systems. See page E337: effects on drug stability * DOI: http://dx.doi.org/10.1208/pt060243
	International search	[Y]WO2007024612 (ARRAY BIOPHARMA INC [US], et al);
		[Y]US2007197478 (JONES PETER [GB], et al);
		[Y]US2008008682 (CHONG LEE S [US], et al)
	by applicant	US4120649
		US4665077
		WO2007024612
		- MAIONE ET AL., CANCER RES., (1990), vol. 51, pages 2077 - 2083
		- TOLMA ET AL., J. CELL IOL., (1993), vol. 122, pages 497 - 511
		- TOLSMA ET AL., J. CELL BIOL., (1993), vol. 122, pages 497 - 511
		- SAGE ET AL., J. CELL. BIOCHEM., (1995), vol. 57, pages 1329 - 1334
		- CAO, PROG MOL SUBCELL BID., (1998), vol. 20, pages 161 - 176
		- BROOKS ET AL., SCIENCE, (1994), vol. 264, pages 569 - 571
		- HAMMES ET AL., NATURE MEDICINE, (1996), vol. 2, pages 529 - 533
		- MIN ET AL., CANCER RES., (1996), vol. 56, pages 2428 - 33
		- CROWLEY ET AL., PROC NATL ACAD SCI., (1993), vol. 90, pages 5021 - 25

The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.

Legal notice
Terms of use
24.2.25; 34p